Statements in this article represent the views of the authors and do not constitute official positions or policies of the Paul-Ehrlich-Institut.
Bioseparations and Downstream Processing
Porcine circovirus (PCV) removal by Q sepharose fast flow chromatography
Version of Record online: 20 SEP 2013
© 2013 American Institute of Chemical Engineers
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Volume 29, Issue 6, pages 1464–1471, November/December 2013
How to Cite
Yang, B., Wang, H., Ho, C., Lester, P., Chen, Q., Neske, F., Baylis, S. A. and Blümel, J. (2013), Porcine circovirus (PCV) removal by Q sepharose fast flow chromatography. Biotechnol Progress, 29: 1464–1471. doi: 10.1002/btpr.1804
- Issue online: 10 DEC 2013
- Version of Record online: 20 SEP 2013
- Accepted manuscript online: 29 AUG 2013 05:48AM EST
- Manuscript Revised: 15 AUG 2013
- Manuscript Received: 19 APR 2013
- 2European Medicines Agency. European Medicines Agency sees no safety concerns with the Rotarix oral vaccine. 2010. Doc. Ref. EMA/CHMP/201923/2010. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/03/WC500078280.pdf (accessed August 6, 2013).
- 9Food and Drug Administration. Points to consider in the manufacture and testing of monoclonal antibody products for human use. 1997. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/OtherRecommendationsforManufacturers/UCM153182.pdf (accessed August 6, 2013).
- 10International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. 1998. Doc. Ref. ICHQ5A(R1). Available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5A_R1/Step4/Q5A_R1__Guideline.pdf (accessed August 6, 2013).
- 11European Medicines Agency. Guideline on virus safety evaluation of biotechnological investigational medicinal products. 2008. Doc. Ref. EMEA/CHMP/BWP/398498/2005. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003795.pdf (accessed August 6, 2013).
- 13Resistance of porcine circovirus to gamma irradiation. BioPharm International. 2001;14:32–36., .
- 19Proceedings of the 2009 viral clearance symposium. Dev Bio (Basel). 2010;133:77–91., , . , , , .
- 33An overview of viral filtration in biopharmaceutical manufacturing. Eur J Parent Sci. 2002;7:72–78., .
- 35European Medicines Agency. European Medicines Agency confirms positive benefit-risk balance of Rotarix. 2010. Doc. Ref. EMA/CHMP/462029/2010. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/07/WC500094972.pdf (accessed August 6, 2013).
- 38Food and Drug Administration. Guidance for Industry Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. 2010. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM202439.pdf (accessed August 6, 2013).
- 39European Pharmacopoeia Commission. General Text 5.2.3. Cell substrates for the production of vaccines for human use. In European Pharmacopoia 7th ed. Strasbourg, Council of Europe; 2010.
- 40European Medicines Agency. Concept paper for a guideline on the quality of porcine trypsin used in the manufacture of human biological medicinal products. 2011. Doc. Ref. EMEA/CHMP/BWP/367751/2011. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/10/WC500116261.pdf (accessed August 6, 2013).